Algert Global LLC Has $3.96 Million Stock Position in 10x Genomics $TXG

Key Points

• Algert Global LLC decreased its stake in 10x Genomics by 31.4%, now holding approximately $3.96 million worth of shares after selling 207,333 shares in Q1.
• Other institutional investors, including ARK Investment Management and Vanguard Group, have increased their positions in 10x Genomics, highlighting strong interest from major players.
• The company reported better-than-expected earnings with a revenue of $172.91 million in its latest quarterly results, significantly exceeding estimates.

Algert Global LLC decreased its stake in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 31.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 453,287 shares of the company's stock after selling 207,333 shares during the period. Algert Global LLC owned approximately 0.37% of 10x Genomics worth $3,957,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of TXG. RA Capital Management L.P. acquired a new position in 10x Genomics during the 4th quarter valued at about $47,092,000. D. E. Shaw & Co. Inc. acquired a new position in 10x Genomics during the 4th quarter valued at about $17,499,000. Two Sigma Investments LP increased its stake in 10x Genomics by 291.2% during the 4th quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company's stock valued at $18,948,000 after buying an additional 982,203 shares during the period. ARK Investment Management LLC increased its stake in 10x Genomics by 7.5% during the 1st quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company's stock valued at $112,143,000 after buying an additional 901,656 shares during the period. Finally, Two Sigma Advisers LP increased its stake in 10x Genomics by 240.6% during the 4th quarter. Two Sigma Advisers LP now owns 1,236,200 shares of the company's stock valued at $17,752,000 after buying an additional 873,200 shares during the period. Institutional investors and hedge funds own 84.68% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on TXG. Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the company a "hold" rating in a research note on Friday, August 8th. Barclays reissued an "overweight" rating and set a $15.00 target price (up previously from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. Canaccord Genuity Group set a $16.00 target price on shares of 10x Genomics in a research note on Monday, August 11th. Stephens reissued an "overweight" rating and set a $14.00 target price on shares of 10x Genomics in a research note on Thursday, May 15th. Finally, Bank of America lifted their price objective on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Thursday, June 26th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, 10x Genomics currently has an average rating of "Hold" and a consensus price target of $13.54.

10x Genomics Price Performance

Shares of TXG traded down $0.23 during mid-day trading on Monday, hitting $14.07. The company's stock had a trading volume of 1,648,401 shares, compared to its average volume of 3,406,161. The firm has a 50-day moving average price of $12.65 and a 200 day moving average price of $10.62. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -20.10 and a beta of 2.03. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.63. The company had revenue of $172.91 million for the quarter, compared to analysts' expectations of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The business's revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, equities analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.